A gene variant carried by millions of people may cause antidepressants to quietly speed up heart valve damage — and most doctors have no idea it exists.
Story Snapshot
- Columbia University researchers found a link between a specific gene variant, SSRI antidepressant use, and faster heart valve damage requiring surgery at a younger age.
- The effect only appears in patients who already have a leaky heart valve and carry two copies of the “long” version of a gene called 5-HTTLPR.
- Lab studies on mice and 122 human heart valve samples confirmed the biological mechanism behind the damage.
- The researchers say SSRIs remain safe for most people, but call for genetic screening in patients with degenerative mitral valve disease.
What the Mitral Valve Does and Why It Matters
The mitral valve sits between two chambers of your heart. It opens and closes with every heartbeat to keep blood moving in the right direction. When it wears down and leaks — a condition called degenerative mitral regurgitation — blood flows backward. Over time, that puts the heart under serious strain. Millions of Americans live with some degree of this condition, and for many, surgery eventually becomes unavoidable.
What researchers at Columbia University discovered is that for a specific group of these patients, the clock may be ticking faster than anyone realized — and a common antidepressant may be part of the reason why.
The Gene That Changes Everything
The study, published in Science Translational Medicine in January 2023, focused on a gene variant called 5-HTTLPR. This gene controls a protein called the serotonin transporter, or SERT. SERT’s job is to clear serotonin out of cells after it has done its work. Some people carry a “long” version of 5-HTTLPR that makes SERT less active. Carry two copies of it — the “long-long” combination — and your SERT works even less effectively.
How Serotonin Damages the Valve in This Genetic Group
When SERT is sluggish, serotonin builds up in the mitral valve cells. That extra serotonin triggers receptors in the valve to produce too much collagen. Collagen is a structural protein, and too much of it in the wrong place changes the shape and stiffness of the valve. Researchers confirmed this by studying 122 human mitral valve samples. Valve cells from patients with the “long-long” variant reacted to serotonin by overproducing collagen in a way that healthy valve cells did not.
Where SSRIs Enter the Picture
Selective serotonin reuptake inhibitors, commonly called SSRIs, are the most widely prescribed antidepressants in the country. They work by blocking SERT — the same protein that is already underperforming in “long-long” patients. So in someone who already has a sluggish SERT and a degenerating mitral valve, taking an SSRI may push the system further in the wrong direction. The Columbia team found that “long-long” patients taking SSRIs needed valve surgery at a significantly younger age than those not taking SSRIs.
Mouse Studies Confirmed the Mechanism
The researchers did not stop at human data. They tested the same idea in mice bred without functional SERT, and in normal mice treated with fluoxetine, a common SSRI. Both groups showed accelerated mitral valve remodeling compared to untreated mice. That animal evidence is important. The human data shows a strong association, but the mouse models provide the mechanistic backbone — the “why” behind the timing difference seen in surgery records.
Critical Limits the Headlines Often Miss
The researchers were careful to draw a clear boundary around their findings. SSRIs do not appear to damage healthy mitral valves. The “long-long” variant alone does not cause valve disease. The risk is specific: patients who already have degenerative mitral regurgitation and carry the “long-long” genotype may face faster progression when taking SSRIs. Dr. Ferrari, who led the study, put it plainly — once the valve has started to degenerate, it may become more vulnerable to serotonin when SERT is already weak.
That nuance matters enormously. Millions of people take SSRIs safely every day. Abandoning antidepressants based on a misread headline would cause real harm. The study’s actual recommendation is targeted: patients with known degenerative mitral valve disease may benefit from genetic screening before starting or continuing SSRI therapy. No current clinical guidelines require that screening, which is the real gap this research exposes.
What Needs to Happen Next
The Columbia team worked with Children’s Hospital of Philadelphia, the University of Pennsylvania, and Valley Hospital Heart Institute — a serious, multi-institution effort funded by the National Heart, Lung and Blood Institute. That gives the findings credibility. But the study still needs independent replication in a separate patient population before genetic screening becomes standard practice. The mechanism is solid. The human association is compelling. The next step is confirming it holds across a broader, genetically screened cohort — and that work has not yet been published.
The Bigger Picture for Patients Over 40
If you are over 40, take an antidepressant, and have ever been told you have a heart murmur or mitral valve issue, this research is worth a conversation with your cardiologist. Not a reason to stop medication — that decision should never be made alone. But a reason to ask whether your specific genetic profile and valve health have ever been considered together. Science is increasingly showing that the same drug can be safe for one person and risky for another based on genes most of us have never been tested for. This study is one more piece of that larger, important puzzle.
Sources:
sciencedaily.com, columbiasurgery.org, science.org, medicalxpress.com, ferrarilabcolumbia.com
